Cargando…
Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents
Mucormycosis is a fungal infection which got worsens with time if not diagnosed and treated. The current COVID-19 pandemic has association with fungal infection specifically with mucormycosis. Already immunocompromised patients are easy target for COVID-19 and mucormycosis as well. COVID-19 infectio...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734071/ https://www.ncbi.nlm.nih.gov/pubmed/36566630 http://dx.doi.org/10.1016/j.ejmech.2022.115010 |
_version_ | 1784846508576735232 |
---|---|
author | Hussain, Mohd Kamil Ahmed, Shaista Khan, Andleeb Siddiqui, Arif Jamal Khatoon, Shahnaaz Jahan, Sadaf |
author_facet | Hussain, Mohd Kamil Ahmed, Shaista Khan, Andleeb Siddiqui, Arif Jamal Khatoon, Shahnaaz Jahan, Sadaf |
author_sort | Hussain, Mohd Kamil |
collection | PubMed |
description | Mucormycosis is a fungal infection which got worsens with time if not diagnosed and treated. The current COVID-19 pandemic has association with fungal infection specifically with mucormycosis. Already immunocompromised patients are easy target for COVID-19 and mucormycosis as well. COVID-19 infection imparts in weak immune system so chances of infection is comparatively high in COVID-19 patients. Furthermore, diabetes, corticosteroid medicines, and a weakened immune system are the most prevalent risk factors for this infection as we discussed in case studies here. The steroid therapy for COVID-19 patients sometimes have negative impact on the patient health and this state encounters many infections including mucormycosis. There are treatments available but less promising and less effective. So, researchers are focusing on the promising agents against mucormycosis. It is reported that early treatment with liposomal amphotericin B (AmB), manogepix, echinocandins isavuconazole, posacanazole and other promising therapeutic agents have overcome the burden of mucormycosis. Lipid formulations of AmB have become the standard treatment for mucormycosis due to their greater safety and efficacy. In this review article, we have discussed case studies with the infection of mucormycosis in COVID-19 patients. Furthermore, we focused on anti-mucormycosis agents with mechanism of action of various therapeutics, including coverage of new antifungal agents being investigated as part of the urgent global response to control and combat this lethal infection, especially those with established risk factors. |
format | Online Article Text |
id | pubmed-9734071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97340712022-12-12 Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents Hussain, Mohd Kamil Ahmed, Shaista Khan, Andleeb Siddiqui, Arif Jamal Khatoon, Shahnaaz Jahan, Sadaf Eur J Med Chem Article Mucormycosis is a fungal infection which got worsens with time if not diagnosed and treated. The current COVID-19 pandemic has association with fungal infection specifically with mucormycosis. Already immunocompromised patients are easy target for COVID-19 and mucormycosis as well. COVID-19 infection imparts in weak immune system so chances of infection is comparatively high in COVID-19 patients. Furthermore, diabetes, corticosteroid medicines, and a weakened immune system are the most prevalent risk factors for this infection as we discussed in case studies here. The steroid therapy for COVID-19 patients sometimes have negative impact on the patient health and this state encounters many infections including mucormycosis. There are treatments available but less promising and less effective. So, researchers are focusing on the promising agents against mucormycosis. It is reported that early treatment with liposomal amphotericin B (AmB), manogepix, echinocandins isavuconazole, posacanazole and other promising therapeutic agents have overcome the burden of mucormycosis. Lipid formulations of AmB have become the standard treatment for mucormycosis due to their greater safety and efficacy. In this review article, we have discussed case studies with the infection of mucormycosis in COVID-19 patients. Furthermore, we focused on anti-mucormycosis agents with mechanism of action of various therapeutics, including coverage of new antifungal agents being investigated as part of the urgent global response to control and combat this lethal infection, especially those with established risk factors. Published by Elsevier Masson SAS. 2023-01-15 2022-12-10 /pmc/articles/PMC9734071/ /pubmed/36566630 http://dx.doi.org/10.1016/j.ejmech.2022.115010 Text en © 2022 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hussain, Mohd Kamil Ahmed, Shaista Khan, Andleeb Siddiqui, Arif Jamal Khatoon, Shahnaaz Jahan, Sadaf Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents |
title | Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents |
title_full | Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents |
title_fullStr | Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents |
title_full_unstemmed | Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents |
title_short | Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents |
title_sort | mucormycosis: a hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734071/ https://www.ncbi.nlm.nih.gov/pubmed/36566630 http://dx.doi.org/10.1016/j.ejmech.2022.115010 |
work_keys_str_mv | AT hussainmohdkamil mucormycosisahiddenmysteryoffungalinfectionpossiblediagnosistreatmentanddevelopmentofnewtherapeuticagents AT ahmedshaista mucormycosisahiddenmysteryoffungalinfectionpossiblediagnosistreatmentanddevelopmentofnewtherapeuticagents AT khanandleeb mucormycosisahiddenmysteryoffungalinfectionpossiblediagnosistreatmentanddevelopmentofnewtherapeuticagents AT siddiquiarifjamal mucormycosisahiddenmysteryoffungalinfectionpossiblediagnosistreatmentanddevelopmentofnewtherapeuticagents AT khatoonshahnaaz mucormycosisahiddenmysteryoffungalinfectionpossiblediagnosistreatmentanddevelopmentofnewtherapeuticagents AT jahansadaf mucormycosisahiddenmysteryoffungalinfectionpossiblediagnosistreatmentanddevelopmentofnewtherapeuticagents |